centerforbiosimilars8h
No Disease Activity Changes After Children With IBD Switched to Infliximab Biosimilar
A real-world study in adolescent and young adult patients with inflammatory bowel disease (IBD) found no significant ...
centerforbiosimilars2d
Robert Spina, MBA
The Top 5 Biosimilar Articles for the Week of December 2 ...
centerforbiosimilars3d
Christina Corridon, MPH, MBA
The Top 5 Biosimilar Articles for the Week of December 2 ...
centerforbiosimilars3d
Mayuri Mathuria, MBA
The Top 5 Biosimilar Articles for the Week of December 2 ...
centerforbiosimilars3d
Cost-Benefits, Efficacy of Biosimilar Ranibizumab vs Aflibercept for nAMD in Japan
When compared with reference aflibercept, a biosimilar ranibizumab was a clinically effective and cost-saving alternative in ...
centerforbiosimilars4d
Prateek Yadav, MPTh, MBA
The Top 5 Biosimilar Articles for the Week of December 2 ...
centerforbiosimilars4d
A Banner Year for Biosimilars: The 19 FDA Approvals From 2024
In 2024, the FDA approved 19 biosimilars across various therapeutic areas, including the first biosimilars for ustekinumab ...
centerforbiosimilars5d
Gary Fanjiang, MD, MBA, MS
The Top 5 Biosimilar Articles for the Week of December 2 ...
centerforbiosimilars5d
Courtney Flaherty
The Top 5 Biosimilar Articles for the Week of December 2 ...
centerforbiosimilars5d
Dinakaran Balasubramanian
The Top 5 Biosimilar Articles for the Week of December 2 ...
centerforbiosimilars5d
Nancy J. Globus, PharmD
The Top 5 Biosimilar Articles for the Week of December 2 ...